Swiss health care company Roche has agreed to acquire Telavant Holdings for $7.1 billion. Telavant produces drugs for inflammatory and fibrotic diseases and is developing a new therapy for Crohn's disease. Roche plans to start global Phase 3 trials for the RVT-3101 drug, which is being developed for Inflammatory Bowel Disease, once it gains full rights. Roche's CEO Teresa Graham expressed confidence in the potential of the antibody and aims to bring it to market in the US and Japan. Roche will also collaborate with Pfizer on a new inflammatory bowel disease drug.

The post Swiss pharma Giant Roche Agrees $7.1 billion deal to Buy Telavant Holdings appeared first on Balanced News Summary.